期刊
ONCOLYTIC VIROTHERAPY
卷 3, 期 -, 页码 83-91出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OV.S47143
关键词
oncolytic virus; cell carrier; immune cells; cancer therapy; myeloid-derived suppressor cells
类别
资金
- NCI NIH HHS [R01 CA140243, R01 CA127483, R01 CA109322] Funding Source: Medline
Oncolytic virotherapy on its own has numerous drawbacks, including an inability of the virus to actively target tumor cells and systemic toxicities at the high doses necessary to effectively treat tumors. Addition of immune cell-based carriers of oncolytic viruses holds promise as a technique in which oncolytic virus can be delivered directly to tumors in smaller and less toxic doses. Interestingly, the cell carriers themselves have also demonstrated antitumor effects, which can be augmented further by tailoring the appropriate oncolytic virus to the appropriate cell type. This review discusses the multiple factors that go into devising an effective, cell-based delivery system for oncolytic viruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据